纳灵含有纳灵的Flammulina velutipes丁-葡萄糖复合体凝系统:结构调节和双重降脂机制
Simin Feng1, Shuqi Liang2, Jianyu Yang2
1Department of Food Science and Engineering, Zhejiang University of Technology, Hangzhou 310014 Zhejiang, People's Republic of China; Key Laboratory of Food Macromolecular Resources Processing Technology Research (Zhejiang University of Technology), China National Light Industry.
Food chemistry
|August 7, 2025
概括
来自Flammulina velutipes的新型基-葡萄糖复合物 (CGC) 水凝被开发用于降低脂质. 这种协同作用的系统增强了胆固醇吸附和药物释放,用于代谢障碍干预.
科学领域:
- 生物材料科学 生物材料科学
- 食品科学与技术 食品科学与技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 代谢障碍,包括失脂症,是全球健康面临的重大挑战.
- 基于多糖的材料为开发新型治疗策略提供了潜力.
- 来自的基-葡萄糖复合物 (CGC) 是一种有前途的生物聚合物,具有可调节性质.
研究的目的:
- 开发一个协同降脂系统,使用结构优化的基-葡萄糖复合体 (CGC).
- 为了研究衍生水凝的物理化学特性和功能性能.
- 评估系统对脂质吸附和控制药物释放的能力,以进行代谢干预.
主要方法:
- 来自Flammulina velutipes的CGC的绿色制剂和酶处理.
- 结构特征包括乙化,结晶性,分子量和水凝多孔性.
- 纳入纳宁 (NAR) 和评估释放动力学和胆汁盐和胆固醇的吸附效率.
主要成果:
- 优化的CGC3表现出增强的乙化,结晶性和分子量.
- 衍生的水凝 (凝-CGC3) 显示出密集的多孔网络,机械稳定性和受控的NAR释放.
- 该系统显示,由于最大限度的结合部位暴露,胆固醇和胆盐的吸附性优越.
结论:
- 结构精制的基-葡萄糖复合液凝系统协同地结合了脂质吸附和生物代谢.
- 这种基于多糖的平台强调了结构功能关系对于代谢障碍干预的重要性.
- 开发的系统显示出作为一种功能性食品成分或治疗剂来管理脂质代谢的潜力.
相关概念视频
01:06Oral Hypoglycemic Agents: Glinides
263
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
263
01:23Dipeptidyl Peptidase 4 Inhibitors
260
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
260
01:24Glucagon-like Receptor Agonists
419
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
419
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
262
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
262
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
873
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
873